TEVA PHARMACEUTICAL INDUSTRIES LTD. AND PROTALIX BIOTHERAPEUTICS LTD. ANNOUNCE A COLLABORATION AGREEMENT FOR THE DEVELOPMENT OF TWO BIOPHARMACEUTICALS, BASED ON PROTALIX'S RECOMBINANT PLANT CELL EXPRESSION TECHNOLOGY

Teva Pharmaceutical Industries Ltd. and Protalix Biotherapeutics Ltd. have signed a collaboration and licensing agreement for the development of two proteins, using Protalix's plant cell culture platform. The undisclosed proteins, aimed at large-sized markets are not part of Protalix's current product development pipeline. BioSpace (http://home.businesswire.com/portal/site/biospace/index.jsp?epi-content=GENERIC&newsId=20060926005995&ndmHsc=v2*A1158663600000*B1159317449000*DgroupByDate*J2*N1003674&newsLang=en&beanID=1121007625&viewID=news_view)